Department of Oncology/Haematology, Division of Haematology, Niguarda Ca'Granda Hospital, Piazza Ospedale Maggiore 3, Milan, Italy.
Expert Rev Hematol. 2010 Apr;3(2):131-48. doi: 10.1586/ehm.10.7.
Bendamustine is an old bifunctional alkylating agent that also has potential antimetabolite properties, and only partial cross-resistance with other alkylators. Although it was synthesized in 1963 only few validated study results exist from this early period. More recently, its peculiar mechanism of action has reawakened interest in this drug that has been extensively studied in indolent non-Hodgkin lymphoma (NHL) and in chronic lymphocytic leukemia (CLL). Experience has also been reported in high-grade NHL and Hodgkin disease. Based on its unique structure, various strategies can be used for mechanism-based combination chemotherapeutic regimens with bendamustine. Moreover, data indicates that bendamustine when combined with rituximab is a valid therapeutic choice for patients with CLL or low-grade NHL demonstrating refractoriness to standard chemotherapy regimens. Furthermore, its documented favorable toxicity profile makes it a particularly useful treatment option for elderly patients.
苯达莫司汀是一种古老的双功能烷化剂，也具有潜在的抗代谢物特性，与其他烷化剂仅有部分交叉耐药性。尽管它于 1963 年合成，但早期仅有少数经过验证的研究结果。最近，其独特的作用机制重新引起了人们对该药的兴趣，该药已在惰性非霍奇金淋巴瘤（NHL）和慢性淋巴细胞白血病（CLL）中进行了广泛研究。在高级别 NHL 和霍奇金病中也有报道。基于其独特的结构，可以使用各种策略将苯达莫司汀与基于机制的联合化疗方案联合使用。此外，数据表明，对于对标准化疗方案有耐药性的 CLL 或低级别 NHL 患者，苯达莫司汀联合利妥昔单抗是一种有效的治疗选择。此外，其明确的良好毒性特征使其成为老年患者特别有用的治疗选择。
